WO2025226841 - GENE THERAPY APPROACH FOR TREATING DISORDERS ASSOCIATED WITH TNNT2
National phase entry is expected:
Publication Number
WO/2025/226841
Publication Date
30.10.2025
International Application No.
PCT/US2025/026015
International Filing Date
23.04.2025
Title **
[English]
GENE THERAPY APPROACH FOR TREATING DISORDERS ASSOCIATED WITH TNNT2
[French]
APPROCHE DE THÉRAPIE GÉNIQUE POUR LE TRAITEMENT DE TROUBLES ASSOCIÉS À TNNT2
Applicants **
KATE THERAPEUTICS, INC.
Inventors
FIELDEN, Mark
TABEBORDBAR, Mohammadsharif
Priority Data
63/638,086
24.04.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2489 | |
| EPO | Filing, Examination, Granting | 15851 | |
| Japan | Filing, Examination, Granting | 2618 | |
| South Korea | Filing, Examination, Granting | 3015 | |
| USA | Filing, Examination, Granting | 7340 |
Total:
31,313
Contact Us
Abstract[English]
The present invention provides expression cassettes and methods that reduce expression of an endogenous TNNT2 gene while providing a non-mutant TNNT2 transgene (tTNNT2), resulting in greatly increased TNNT2 transgene incorporation in the sarcomere than from delivery of the TNNT2 transgene alone.[French]
La présente invention concerne des cassettes d'expression et des procédés qui réduisent l'expression d'un gène TNNT2 endogène tout en fournissant un transgène TNNT2 non mutant (tTNNT2), ce qui entraîne une incorporation nettement plus importante du transgène TNNT2 dans le sarcomère que lors de l'administration du transgène TNNT2 seul.